Pipeline Review for Rubella (German Measles): H1 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Rubella (German Measles) - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Discovery and Unknown stages are 4, 1, 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Companies MentionedBiological E Ltd Cadila Healthcare Ltd GlaxoSmithKline Plc Indian Immunologicals Ltd Sinovac Biotech Ltd
Key Topics CoveredIntroduction Report Coverage Rubella (German Measles) - Overview Rubella (German Measles) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Rubella (German Measles) - Therapeutics Assessment Assessment by Route of Administration Assessment by Molecule Type Rubella (German Measles) - Companies Involved in Therapeutics Development Biological E Ltd Cadila Healthcare Ltd GlaxoSmithKline Plc Indian Immunologicals Ltd Sinovac Biotech Ltd Rubella (German Measles) - Drug Profiles
For more information about this report visit https://www.researchandmarkets.com/research/wkz5gx/pipeline_review?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005822/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/11/2018 11:46 AM/DISC: 06/11/2018 11:46 AM